Entry Detail

General Information

Database ID: LDA0001040
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:GAS5
Full Name:growth arrest specific 5
Category:LncRNA
Species:Homo sapiens
Synonyms:NCRNA00030|SNHG2
Chromosome:1
Strand:-
Coordinate:
Start Site(bp):173863899End Site(bp):173868882
External Links:
Ensembl ID:ENSG00000234741
Ensembl Transcript ID:N/A
Entrez Gene:60674.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:128   
More Information
Causal Disease Number:78
Network:
Top Causal Diseases:
Ovarian Neoplasms  (Score: 1)
Breast Neoplasms  (Score: 1)
Carcinoma, Non-Small-Cell Lung  (Score: 1)
Breast Neoplasms  (Score: 1)
Colorectal Neoplasms  (Score: 1)
Carcinoma, Hepatocellular  (Score: 1)
Glioma  (Score: 1)
Osteosarcoma  (Score: 1)
Arthritis, Rheumatoid  (Score: 1)
Osteosarcoma  (Score: 1)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:3083D029424
Disease Name:chronic obstructive pulmonary diseasePulmonary Disease, Chronic Obstructive
Category:Disease OntologyMeSH
Type:Respiratory Tract Diseases
Define:An obstructive lung disease that is a chronic and progressive disorder of small airways in the lungs and that is characterized by irreversible airflow obstruction, typically identified by reductions in quantitative spirometric indices, induced forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (less than 0.7 is diagnostic of COPD). Lung volume is increased and pulmonary hypertension may occur. The pathologic changes result in the disruption of the airflow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough and chest tightness. COPD is a consequence (an end result) of chronic bronchitis, emphysema or both.A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
Alias:COLD//COPD//chronic obstructive airway disease//chronic obstructive lung diseasePulmonary Disease, Chronic Obstructive//Chronic Obstructive Lung Disease//Chronic Obstructive Pulmonary Diseases//COAD//COPD//Chronic Obstructive Airway Disease//Chronic Obstructive Pulmonary Disease//Airflow Obstruction, Chronic//Airflow Obstructions, Chronic//Chronic Airflow Obstructions//Chronic Airflow Obstruction

 

Disease Association Statistics

Total Associated ncRNA Number:76   
More Information
Causal ncRNA Number:26
Network:
Top Causal ncRNAs:
TUG1  (Score: 0.985791)
TUG1  (Score: 0.985791)
RUBCNL  (Score: 0.731059)
IL6-AS1  (Score: 0.731059)
GAS5  (Score: 0.731059)
MALAT1  (Score: 0.731059)
LINC00987  (Score: 0.731059)
CASC2  (Score: 0.731059)
hsa_circ_0006872  (Score: 0.731059)
circBPTF  (Score: 0.731059)
More Information

 

Evidence Support

Strong Evidence:Western Blot//qPCR//CCK8//RIP//Luciferase Report Assay//ELISA//IF
Weak Evidence:

 

Reference

[1] PubMed ID:35583006
Disease Name:Pulmonary Disease, Chronic Obstructive
Sample:MRC-5 cell line
Dysfunction Pattern:Interaction(miR‑223‑3p/NLRP3 axis)
Validated Method:Western Blot//qPCR//CCK8//RIP//Luciferase Report Assay//ELISA//Bioinformatics Analysis//IF
Description:Additionally, LPS induced the increase in GAS5 mRNA expression levels and the release of inflammatory factors (IL‑2, IL‑6, IL‑10 and TNF‑α), suggesting that GAS5 is implicated in pyroptosis in COPD. A dual‑luciferase assay demonstrated that GAS5 could directly bind to microRNA‑223‑3p (miR‑223‑3p), and NLRP3 is a direct target of miR‑223‑3p. Furthermore, GAS5 reduced the expression levels of miR‑223‑3p, while it increased the expression levels of NLRP3.
Causality:Yes
Causal Description: Furthermore, upregulation of GAS5 promoted cell death and inhibited proliferation in the MRC‑5 cell line. Additionally, increased GAS5 expression significantly promoted the production of caspase‑1, IL‑1β, IL‑18, cleaved GSDMD and NLR pyrin domain containing protein 3 (NLRP3).
Clinical-realted Application: